Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

Exclusion Criteria

• •Subject with incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study drugs will not be normal
• •Subject with known hypersensitivity to the study drugs (active substances or excipients of the preparations)
• •Subject with known coagulation disorders (e.g. von Willebrand disease, hemophilia)
• •Subject with febrile illness within 1 week before the first study drug administration
• •Subject with suspicion of drug or alcohol abuse
• •Subject with intake of foods or beverages containing grapefruit, pomelo, Seville orange, and tangelo within 1 week before the first study drug administration
• •Subject with therapies (e.g. physiotherapy, acupuncture, etc.) within 1 month before starting study treatment
• •Subject with clinically relevant findings in the electrocardiogram (ECG) such as a second- or third-degree atrioventricular block, prolongation of the QRS complex over 120 msec or of the corrected QT (QTc) interval over 450 msec
• •Subject with systolic blood pressure below 90 or above 130 mmHg
• •Subject with diastolic blood pressure below 45 or above 85 mmHg
• •Subject with clinically relevant deviations of the screened laboratory parameters from reference ranges